The non-genomic effects of the PPARβ/δ agonist GW0742 on STZ treated rat aorta

N. Perez-Diaz, I. Pushkarsky, N. Oweis, L.A. Lione, Louise Mackenzie

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: The ubiquitous nuclear receptor PPARβ/δ is increasingly being studied in regards to numerous diseases including diabetes following on the finding that PPARβ/δ agonist GW0742 controls Type 1 Diabetes in rats. Studies have shown that GW0742 has off target, non- PPARβ/δ effects in the cell although there are some key questions that remain to be addressed in respect to the significance of this control on vascular tone. Methods: Using isometric organ baths, rat aorta rings were exposed to ROCK inhibitors and the changes in contraction and dilation measured. Results: Our data shows that the PPARβ/δ agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and diabetic rat aorta. ROCK inhibitors Fasudil and Y27632 significantly reduced GW0742 mediated dilation of naïve rat aorta, but Fasudil had no effect on GW0742 dilation in STZ treated rat aorta. In contrast, STZ treated rat aorta pre-contracted with high [K+] Krebs lacked a dilatory response to GW0742, which taken together indicates that the mechanism of action of GW0742 mediated dilation changes in the diabetic state compared to non-diabetic state. Conclusion: This is the first direct evidence demonstrating the non- PPARβ/δ effect of GW0742 on contraction is irrespective to the diabetic state, and that GW0742 has the potential to induce vasodilation via multiple off-target mechanisms.
Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalCurrent Molecular Pharmacology
Volume11
Issue number2
DOIs
Publication statusPublished - 31 Dec 2018

Fingerprint

Peroxisome Proliferator-Activated Receptors
Aorta
Dilatation
GW0742
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Phenylephrine
Cytoplasmic and Nuclear Receptors
Type 1 Diabetes Mellitus
Baths
Vasodilation
Blood Vessels

Cite this

Perez-Diaz, N. ; Pushkarsky, I. ; Oweis, N. ; Lione, L.A. ; Mackenzie, Louise. / The non-genomic effects of the PPARβ/δ agonist GW0742 on STZ treated rat aorta. In: Current Molecular Pharmacology. 2018 ; Vol. 11, No. 2. pp. 149-154.
@article{205704e7a3b64e1f9431c8c64317d7cf,
title = "The non-genomic effects of the PPARβ/δ agonist GW0742 on STZ treated rat aorta",
abstract = "Background: The ubiquitous nuclear receptor PPARβ/δ is increasingly being studied in regards to numerous diseases including diabetes following on the finding that PPARβ/δ agonist GW0742 controls Type 1 Diabetes in rats. Studies have shown that GW0742 has off target, non- PPARβ/δ effects in the cell although there are some key questions that remain to be addressed in respect to the significance of this control on vascular tone. Methods: Using isometric organ baths, rat aorta rings were exposed to ROCK inhibitors and the changes in contraction and dilation measured. Results: Our data shows that the PPARβ/δ agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and diabetic rat aorta. ROCK inhibitors Fasudil and Y27632 significantly reduced GW0742 mediated dilation of na{\"i}ve rat aorta, but Fasudil had no effect on GW0742 dilation in STZ treated rat aorta. In contrast, STZ treated rat aorta pre-contracted with high [K+] Krebs lacked a dilatory response to GW0742, which taken together indicates that the mechanism of action of GW0742 mediated dilation changes in the diabetic state compared to non-diabetic state. Conclusion: This is the first direct evidence demonstrating the non- PPARβ/δ effect of GW0742 on contraction is irrespective to the diabetic state, and that GW0742 has the potential to induce vasodilation via multiple off-target mechanisms.",
author = "N. Perez-Diaz and I. Pushkarsky and N. Oweis and L.A. Lione and Louise Mackenzie",
year = "2018",
month = "12",
day = "31",
doi = "10.2174/1874467209666161229124356",
language = "English",
volume = "11",
pages = "149--154",
journal = "Current Molecular Pharmacology",
issn = "1874-4672",
number = "2",

}

The non-genomic effects of the PPARβ/δ agonist GW0742 on STZ treated rat aorta. / Perez-Diaz, N.; Pushkarsky, I.; Oweis, N.; Lione, L.A.; Mackenzie, Louise.

In: Current Molecular Pharmacology, Vol. 11, No. 2, 31.12.2018, p. 149-154.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The non-genomic effects of the PPARβ/δ agonist GW0742 on STZ treated rat aorta

AU - Perez-Diaz, N.

AU - Pushkarsky, I.

AU - Oweis, N.

AU - Lione, L.A.

AU - Mackenzie, Louise

PY - 2018/12/31

Y1 - 2018/12/31

N2 - Background: The ubiquitous nuclear receptor PPARβ/δ is increasingly being studied in regards to numerous diseases including diabetes following on the finding that PPARβ/δ agonist GW0742 controls Type 1 Diabetes in rats. Studies have shown that GW0742 has off target, non- PPARβ/δ effects in the cell although there are some key questions that remain to be addressed in respect to the significance of this control on vascular tone. Methods: Using isometric organ baths, rat aorta rings were exposed to ROCK inhibitors and the changes in contraction and dilation measured. Results: Our data shows that the PPARβ/δ agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and diabetic rat aorta. ROCK inhibitors Fasudil and Y27632 significantly reduced GW0742 mediated dilation of naïve rat aorta, but Fasudil had no effect on GW0742 dilation in STZ treated rat aorta. In contrast, STZ treated rat aorta pre-contracted with high [K+] Krebs lacked a dilatory response to GW0742, which taken together indicates that the mechanism of action of GW0742 mediated dilation changes in the diabetic state compared to non-diabetic state. Conclusion: This is the first direct evidence demonstrating the non- PPARβ/δ effect of GW0742 on contraction is irrespective to the diabetic state, and that GW0742 has the potential to induce vasodilation via multiple off-target mechanisms.

AB - Background: The ubiquitous nuclear receptor PPARβ/δ is increasingly being studied in regards to numerous diseases including diabetes following on the finding that PPARβ/δ agonist GW0742 controls Type 1 Diabetes in rats. Studies have shown that GW0742 has off target, non- PPARβ/δ effects in the cell although there are some key questions that remain to be addressed in respect to the significance of this control on vascular tone. Methods: Using isometric organ baths, rat aorta rings were exposed to ROCK inhibitors and the changes in contraction and dilation measured. Results: Our data shows that the PPARβ/δ agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and diabetic rat aorta. ROCK inhibitors Fasudil and Y27632 significantly reduced GW0742 mediated dilation of naïve rat aorta, but Fasudil had no effect on GW0742 dilation in STZ treated rat aorta. In contrast, STZ treated rat aorta pre-contracted with high [K+] Krebs lacked a dilatory response to GW0742, which taken together indicates that the mechanism of action of GW0742 mediated dilation changes in the diabetic state compared to non-diabetic state. Conclusion: This is the first direct evidence demonstrating the non- PPARβ/δ effect of GW0742 on contraction is irrespective to the diabetic state, and that GW0742 has the potential to induce vasodilation via multiple off-target mechanisms.

U2 - 10.2174/1874467209666161229124356

DO - 10.2174/1874467209666161229124356

M3 - Article

VL - 11

SP - 149

EP - 154

JO - Current Molecular Pharmacology

JF - Current Molecular Pharmacology

SN - 1874-4672

IS - 2

ER -